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ABSTRACT
Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the
antibody’s exquisite speciﬁcity for the target antigen-expressing cancer cell together with the cytotoxic
potency of the payload. Much success stems from the rational design of “toxic warheads”, chemically
linked to antibodies, and from ﬁne-tuning the intricate properties of chemical linkers. Here, we focus on
the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-
tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody
structural attributes present opportunities that may contribute to the success of next generation ADCs.
KEYWORDS
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Introduction
Antibody-Drug Conjugates and known mechanisms of
action in oncology
The treatment of cancer remains a formidable challenge.1
For many tumors, chemotherapy achieves signiﬁcant clinical
beneﬁt, however these agents suffer from lack of speciﬁcity for
cancer cells and high toxicity, often resulting in adverse effects,
poor quality of life, early discontinuation and reduced clinical
efﬁcacy.1 Targeted treatments in the form of tumor antigen-
speciﬁc and checkpoint inhibitor antibodies, envisioned for
over 100 years since Ehrlich proposed the concept of “the
magic bullet”, have now been established in clinical oncology
and have earned their place alongside chemotherapeutic agents
and small molecule inhibitors in the care of cancer patients.1
However, antibodies targeting tumor-associated antigens also
suffer from limitations. These include limited tissue penetrance
and blocking target-associated pathways due to intrinsic and
acquired resistance.2
Antibody-drug conjugates (ADCs) are designed to combine
the selectivity of monoclonal antibodies (mAbs) with the cyto-
toxic potential of chemotherapeutic drugs.3 ADCs are tripartite
drugs, comprising of a tumor antigen-speciﬁc mAb conjugated
to a potent cytotoxin via a stable chemical linker.3 The three
components together give rise to a powerful oncolytic agent,
capable of delivering normally-intolerable cytotoxic drugs
directly and speciﬁcally to cancer cells, guided by the exquisite
speciﬁcity and high afﬁnity of antibodies for their targets in
tumors (Fig. 1).3
ADCs have a well-described mechanism of action, namely
binding of the mAb to the target antigen resulting in complex
internalization through receptor-mediated endocytosis.4 Upon
fusion of two internalized vesicles, an early endosome is formed
whereby cargo is sent through two pathways: recycling which
results in trafﬁcking back to the plasma membrane,5 or endoly-
sosomal degradation.4
The mechanism and location of toxin release depends on
the type of linker. Non-cleavable linkers depend on degrada-
tion of the antibody with or without a portion of the linker to
liberate the toxin from the ADC.6 However, cleavable linkers
can release toxins through acidic conditions in the lysosome,
reduction of the linker in the cytoplasm or cleavage by spe-
ciﬁc proteases.6 For ADCs containing cleavable linkers, the
antibody-part of the ADC is either degraded once the toxin is
cleaved or is recycled and released outside the cell in vesicles.4
Once the toxin is cleaved from the ADC, it enters the cyto-
plasm and can either bind to its molecular target in the cyto-
plasm (usually tubulin) or can cross into the nucleus and
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Figure 1. Schematic of ADC components and their role in ADC design, engineering and functions. The Fab region (A) is responsible for antigen recognition and binding,
and can lead to ADC internalization. Therefore, the Fab region needs to be targeted to tumor-associated antigens that are homogenously expressed on tumor cells, ideally
with little or no expression on normal cells. The payload is attached to the antibody via a cleavable or non-cleavable linker (B). Non-cleavable linkers rely on the complete
degradation of the antibody after internalization of the ADC, whereas most cleavable linkers are cleaved by different mechanisms depending on the linker (i.e. proteases,
reduction) and some cleavable linkers do not depend on ADC internalization for payload release and can result in higher off-target cytotoxicities. The hydrophobicity of link-
ers can play a vital role in the biodistribution of an ADC. Linkers can be attached non-selectively via lysines or the hinge thiols of cysteines, or antibody engineering can be
performed for site-speciﬁc linking. The payload (C) is responsible for ADC toxicity and is usually a small hydrophobic molecule, able to cross cell membranes and cause cell
death by targeting the cytoskeleton or DNA. Once cleaved from the antibody payloads can enter other (tumor) cells, resulting in further tumor killing (i.e. bystander effect)
as well as off-target cytotoxicity when entering normal cells. The Fc region of the antibody (D) can trigger immune effector functions such as Antibody-Dependent Cytotoxic-
ity through binding to Fcg-receptors. However, if the ADC is internalized into non-malignant cells, it can cause off-target cytotoxicity. Antibody engineering can enhance or
impair immune effector functions through, for example, single point mutations, Thiomabs, glycoengineering or incorporation of unnatural amino acids.
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cause cell cycle arrest and apoptosis by interfering with
DNA.7 Almost all payloads in clinical development are small
hydrophobic molecules, that are able to cross biomembranes
once cleaved from the ADC.8 Therefore, nuclear DNA as well
as the cytoskeleton in the cytoplasm are suitable locations for
the payload to interfere with critical cellular mechanisms
resulting in cell death.
The majority of ADCs have clinical efﬁcacy through on-tar-
get on-tumor effects; however some ADCs also cause off-target
on-tumor cell killing, referred to as the bystander-effect.9 This
effect exploits the ability of payloads to cross cell membranes
and exert their cytotoxic effect on neighbouring cancer cells that
lack target antigen expression. The payload may be cleaved from
the antibody in the tumor microenvironment due to local acidic
pH conditions and the presence of proteases released locally by
tumor and dead cells.10 The bystander effect is especially advan-
tageous for heterogeneous tumors consisting of tumor cells with
low or absent target antigen expression that cannot be recog-
nized through the antibody variable regions of the ADC.7,11 The
majority of ADCs internalize, however there are also non-inter-
nalizing ADCs that target tumor cells in the same way but can
exert off-target on-tumor effects, making use of the bystander
mechanism as one of their primary modes of action. However,
this type of ADCs come with a perceived risk of also killing
immune cells, such as antigen-presenting cells, that may be
important in tumor growth restriction, in an off-target fashion.
Since non-internalizing ADCs have had restricted success in the
clinic, internalizing ADCs are still at the forefront of the devel-
opment of targeted anti-cancer therapeutics.3
ADCs in clinical use
After decades of failure with the ﬁrst approved ADCs being
withdrawn from the market due to fatal cytotoxicity,12 ADCs
are now one of the fastest growing ﬁelds of oncology therapeu-
tics. There are currently four FDA- and EMA- approved ADCs
within clinical practice with durable clinical responses reported:
gentuzumab ozogamicin (MylotargTM) targeting CD33
expressed by acute myeloid leukemia (AML) has just been re-
approved in the US, after being withdrawn in 2010,13,14 bren-
tuximab vedotin (AdcetrisTM) which targets CD30 expressed
by Hodgkin lymphoma (HL) and systemic anaplastic large cell
lymphoma (ALCL),15 trastuzumab emtansine (KadcylaTM, also
known as T-DM1) targeting HER2 expressed by 20–25% of
breast carcinomas and other solid tumor types16 and the
recently-approved inotuzumab ozogamicin (BesponsaTM) tar-
geting the B-cell lineage marker CD22, expressed on acute lym-
phoblastic leukemia cells.17 (Table 1). Since their approval,
there has been signiﬁcant growth in this class of oncology ther-
apeutics, with over 65 agents in early and late stage clinical tri-
als (see Table 2 for ADCs in Phase I/II, II and III clinical trials).
Two of the approved ADCs, brentuximab vedotin and tras-
tuzumab emtansine, use auristatin- and maytansinoid-based
warheads, respectively. These microtubule-targeting agents rep-
resent two-thirds of all clinical stage ADC payloads.18 Mirve-
tuximab soravtansine (IMGN853, Phase III) and Depatuximab
mafodotin (ABT-414, Phase IIb/III) also fall into this category
line, consisting of the maytansinoid warhead DM4, similar to
DM1, the drug component of trastuzumab emtansine19 and
MMAF, respectively. The other three ADCs in Phase III clinical
trials (Sacituzumab Govitecan, Rovaltuzumab tesirine, Vadas-
tuximab talirine) consist of drugs that target DNA and are
therefore cytotoxic to both proliferating and non-proliferating
cells (Table 2). SGN-CD33A (recently discontinued)20 and
rovalpituzumab tesirine (Rova-TTM) consist of pyrrolobenzo-
diazepines (PBDs),21,22 payloads designed to interfere with the
minor groove of the DNA. The drug component of IMMU-132
is SN38a camptothean analogue, which inhibits DNA
Table 1. Approved ADCs in clinical use.
ADC Developer Indication
Target
Antigen
Antibody
Type/mutations Linker Cytotoxin Year of approval
Gemtuzumab
ozogamicin
(MylotargTM)
Pﬁzer Acute myeloid
leukemia
CD33 Humanised IgG4 IgG4
k antibody hP67.6
Acid-labile
hydrozone
bifunctional
linker
Calicheamicin FDA Approved in 2000 in
the US, withdrawn in
2010, re-approved
in 2017
Brentuximab vedotin
(AcetrisTM)
Seattle Genetics Relapsed Hodgkin
Lymphoma and
systemic
anaplastic large
cell lymphoma
CD30 Chimeric IgG, fusion
of the variable
heavy and light
region of the
murine anti-CD30
antibody AC10
with the constant
gamma1-heavy
and kappa-light
region of the
human
immunoglobulin
Cathepsin cleavable
valine-citrulline
approx. DAR 4
MMAE Accelerated approval by
the FDA in 2011, full
approval 2015
Trastuzumab
emtansine
(KadcylaTM)
Roche HER2C breast
cancer
HER2 Humanised IgG1
(from mouse)
Non-cleavable
thioether linker,
DAR
3–4
DM1 FDA approved in 2013
Inotuzumab
ozogamicin
(BesponsaTM))
Pﬁzer Acute
lymphoblastic
leukaemia
CD22 Recombinant
humanised IgG4
Acid-labile
hydrozone
Calicheamicin,
CM1
FDA approved in 2017
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Topoisomerase I.23,24 Generally, there is a trend towards pay-
loads with higher potency featuring IC50s in the nanomolar
and sub-nanomolar scale.1 Despite many advances, ﬁnding
novel payloads with optimal in vivo tolerability and high thera-
peutic index is still an ongoing challenge. New classes of toxins,
evaluated in pre-clinical settings, such as the DNA alkylating
agent indolinobenzodiazepine pseudodimers (IGNs), resulted
in promising ADCs characterized by both high in vivo tolera-
bility and high therapeutic indices and has been now moved
forward to clinical evaluation.25
Over the past decade, much research has been conducted
focusing on linker chemistry and optimizing cytotoxic pay-
loads. However, while the antibody is often viewed as a mecha-
nism to deliver the cytotoxic payload, other potential effects
pertaining to the antibody’s unique structural characteristics,
remain less-well elucidated. In this review, we consider the
ADC as a tripartite drug, speciﬁcally focusing on the underex-
plored antibody rather than the toxic payload portion or the
linker.
The Fab regions: Selection of, and speciﬁcity to, target
expression of antigen
The successful development of an ADC is dependent on the
premise of selecting an appropriate target antigen, with its suit-
ability forming a key determinant of the efﬁcacy of the ADC.
Targeted therapies such as ADCs exploit the difference in pro-
tein expression between cancer cells and normal cells in order
to select a suitable target antigen. Current targets being
exploited include HER2 (i.e. trastuzumab emtansine)26 and
CD30 (i.e. brentuximab vedotin).27 It is widely accepted that
the target antigen should be homogeneously and selectively
expressed on the surface of tumor cells with little or no expres-
sion on normal tissues in order to limit on-target off-tumor
toxicity.28
Target validation for ADCs must be based upon the reliable
identiﬁcation of target antigens. Genomic studies have
highlighted the complex heterogeneity in tumors with different
cell sub-populations harboring distinct phenotypic diversity
resulting from the integration of genetic and non-genetic inﬂu-
ences that deﬁne intra-tumor and inter-tumor heterogeneity.29
This represents a profound challenge for antigen selection and,
combined with sampling bias, may negatively impact drug dis-
covery and validation of suitable antigen targets for ADCs.29
While homogeneous target antigen expression is not an abso-
lute requirement for ADC efﬁcacy, since heterogeneous tumors
may beneﬁt from bystander killing, the most advanced ADCs
within clinical development are for hematological indications
which have a largely consistent expression of lineage speciﬁc
markers (i.e. CD22, CD30)30, such as CD79b (RG-7596,
DCDS4501A). These lineage speciﬁc markers of hematologic
cells are also targets for three out of four approved ADCs:
CD22 (BesponsaTM) for the treatment of acute lymphoblastic
leukemia, CD30 (AcetrisTM) for the treatment of relapsed
Hodgkin Lymphoma and systemic anaplastic large cell lym-
phoma and CD33 (MylotargTM) for the treatment of acute
myeloid leukemia (Table 2).31
Traditionally, interest in target antigens has largely focused
on those expressed on tumor cells. However, there has been
growing interest in targeting antigens present within the tumor
microenvironment, including those within the neovasculature,
sub-endothelial extracellular matrix and the tumor stroma.32–34
ADCs that target the stroma cause tumor cell death by reducing
the concentration of growth factors produced by the stroma.35
Since all tumor cells are dependent on angiogenesis and stro-
mal factors for their survival, ADCs that target such tissues
may have a broader efﬁcacy. This is particularly attractive due
to the fact that, unlike cancer cells, these cells are genomically
stable, and are less likely to develop mutation-related drug
resistance.3
The target antigen should be well internalized by receptor-
mediated endocytosis and should not be down-regulated by
endocytosis or by the effects of repeated stimulation during
treatment.1,36 In order for an ADC to generate a clinical effect,
antibody recognition of its epitope on the antigen must result
in endocytosis.37 In general, antigens that internalize well, with
low expression on normal tissue and high expression on tumors
are preferred for an ADC approach as they minimize potential
toxicity through unwanted on-target, off-tumor expression.
However the results of clinical trials indicate it may be difﬁcult
to predict the toxicity based on target expression in healthy tis-
sue and toxicities due to off-tumor on-target expression can
occur.38 In the case of glembatumumab vedotin that targets the
transmembrane glycoprotein NMB (gpNMB) on cancer cells,
development of skin rash was one of the observed dose-limiting
toxicities, which is likely due to membrane expression of
gpNMB in epithelial cells of the skin. Previously the develop-
ment of an ADC directed against CD44v6 was discontinued
due to severe skin toxicity linked to high CD44v6 expression in
the skin.39,40 Interestingly, unlike ﬁndings with unconjugated
antibody functions, current experimental evidence generally
suggests that the antigen density does not directly correlate
with the efﬁcacy of the ADC.41 Studies of lymphoma, mela-
noma and prostate cancer have demonstrated no direct correla-
tion between antigen density and therapeutic response for
ADCs, and ﬁndings suggest that a minimum antigen expres-
sion threshold is required for ADC efﬁcacy.31,42,43
The location and roles of the linker: Considerations for
conjugation strategies
The linker plays a central role in connecting the cytotoxic agent
to the antibody structure. One of the key functions of the linker
is to maintain complex stability in the blood circulation, while
allowing toxin release upon ADC internalization by target cells.
The ﬁrst generation of ADCs mostly relied on linking via the
antibody’s lysine or cysteine residues.6 IgG1 isotype antibodies
consist of approximately 90 lysine residues, however, due to
structural constrains, only 30 can be modiﬁed.8 Therefore, link-
ing the antibody to the toxin via the lysine residues results in
heterogeneous ADCs with regards to both the number of toxins
conjugated per antibody (drug-to-antibody ratio, DAR) and the
positions of conjugation within the structure. Furthermore,
monitoring changes on the antibody scaffold may be challeng-
ing, since, in addition to batch-to-batch variations, ADCs
within one batch could differ signiﬁcantly.44 Therefore, novel
methods are being developed to improve protein characteriza-
tion and control protein modiﬁcation processes.45 Nevertheless,
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KadcyclaTM would not be a product unless regulatory authori-
ties were satisﬁed that the conjugate product could be made
consistently.
When conjugating to cysteine residues, disulﬁde bonds
within the antibody must be reduced in order to produce free
thiols for conjugation.46 IgG1 antibodies consist of 4 inter-
chain disulﬁde bonds – two connecting heavy and light chains
and two connecting the two heavy chains in the hinge region,
keeping the two half-antibodies together.47 There are also 12
intra-chain disulﬁde bonds, however it has been shown that
mild reduction of the antibody with DTT (Dithiothreitol) or
TCEP (Tris(2-Carboxyethyl)phosphine) will result in inter-
chain bonds being reduced without having an impact on the
intra-chain disulﬁde bonds of the antibody.48 However, one of
the pitfalls of partial antibody reduction may be loss of the light
chain, which can impair the binding properties of the ADC as
well as its antigen cross-linking properties which may be key to
facilitating internalization.
The location of the linker on the antibody structure could
also negatively impact ADC functions. If the linker is conju-
gated near the Fab antigen binding site, this may interfere with
or completely block antigen recognition and hence targeting of
the ADC to tumors. Conjugation at or near the Fc regions, may
also hinder binding to the neonatal Fc receptor (FcRn) and/or
Fc receptors on immune effector cells, or alter antibody folding
and structure. Either individually or collectively, these could
substantially modify pharmacokinetics, pharmacodynamic
properties, target recognition and engagement, effector func-
tions and consequently bioavalability and efﬁcacy. Quantifying
the impact of these effects may be particularly complex for het-
erogeneous ADC preparations designed from lysine or cysteine
bound linkers.
Despite drawbacks, cysteine and lysine conjugated heteroge-
neous ADC products with complex structural characteristics
and variable DARs have facilitated ADC design and clinical
translation. Current trends are focused on: designing homoge-
nous ADC products with deﬁned DARs via site-speciﬁc conju-
gation;8 increasing the polarity and decreasing hydrophobicity
of linkers which can provide improved pharmacokinetics, solu-
bility and a larger therapeutic window.49 Furthermore, ADCs
with higher DARs can have improved potency because of
greater delivery of toxin per antibody bound and may have the
potential to eradicate off-target tumor cells, but can suffer from
drawbacks including increased plasma clearance and off-target
cytotoxicity.50
Site-speciﬁc engineering may be achieved by integrating
additional cysteines or non-natural amino acids with reactive
groups for linking payloads.8 Thiomab-ADCs, for example,
contain engineered cysteines for site-speciﬁc conjugation giving
a controlled DAR of 2, and have improved homogeneity as well
as improved efﬁcacy and toxicity proﬁles as demonstrated in
vivo in cynomolgus monkey studies.51–53
The trend towards homogenous ADC design enables the
emergence of novel bio-orthogonal chemistries that utilize
reactive moieties other than thiols or amines, and is broadening
the diversity of linking methods.8 Shifting the focus by investi-
gating the impact of the antibody scaffold for ADC design
might result in future ADCs with: deﬁned DARs, higher solu-
bility, lower off-target toxicity, better-characterized structural
and functional attributes and improved efﬁcacy. Therefore, the
challenge is to design linking strategies that retain antibody
structural integrity and stability, recognition and afﬁnity for
the target, Fc-mediated attributes that complement and
enhance bioavailability and anti-tumor functions.
The Fc regions: Antibody scaffold and potential
inﬂuence on function
The main role of the antibody moiety of an ADC is to deliver
the cytotoxic drug selectively to the target cells due to its speci-
ﬁcity and high afﬁnity for an antigen expressed on the surface
of target cells. Therefore, in designing ADCs, much attention
has been paid to the Fab portion of the antibody, responsible
for antigen recognition. The antibodies used to develop ADCs
are mainly full length recombinant monoclonal antibodies,
almost exclusively of the IgG class. Yet the Fc domains of such
agents have received less consideration.
Contributions to efﬁcacy
The Fc portion of IgG antibodies contains the binding domain
to the neonatal Fc receptor (FcRn) that regulates serum half-
life, and recognition of different activating and inhibitory Fc
receptors on immune effector cells that can inﬂuence bioavail-
ability, sequestration to tissues, trafﬁcking to tumors, antigen-
targeting and immune functions.
An intact IgG ADC might be able to recruit and activate
complement components and immune effector cells into the
tumor site, mediating secondary immune functions such as
complement dependent cytotoxicity (CDC), antibody depen-
dent cell-mediated cytotoxicity (ADCC) and antibody depen-
dent cell-mediated phagocytosis (ADCP).54 The ability of
ADCs to trigger immune effector functions could offer an
advantage through anti-tumor activity, or a disadvantage by
sequestering ADCs through immune cells in the circulation
and affecting the localization and target cell internalization of
ADCs at the tumor site, or by being internalized by immune
cells resulting in off-target toxicity. Studies have demonstrated
similar antibody-mediated effector functions between the
naked antibody and the corresponding ADC. For instance, the
capacity of trastuzumab to induce ADCC of breast cancer cells
was not affected by conjugation to DM1,55 while brentuximab
has been described to induce ADCP in vivo, believed to con-
tribute to the potent anti-tumor efﬁcacy observed for the bren-
tuximab vedotin ADC.56,57 While Fc receptor binding can be
advantageous, other studies have identiﬁed Fc receptor engage-
ment as a possible cause of side effects of ADC therapeutics.
T-DM1 has been demonstrated to be internalized by megakar-
yocytes in vivo via FcgRIIa binding. This has been proposed to
be involved in the development of thrombocytopenia induced
by T-DM1.58,59 However, there are other mechanisms besides
FcgRIIa binding, such as macropinocytosis, which could also
account for sufﬁcient non-receptor/non-target mediated uptake
by megakaryocytes to cause thrombocytopenia.59
For these reasons, depending on the type of tumor, the
expression of the antigen and the afﬁnity of the antibody for its
antigen, it might be appropriate to design an ADC with deﬁned
Fc-mediated functions either able or unable to engage with the
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immune system. ADCs can therefore be designed by selecting
an appropriate subclass of IgG or by engineering the Fc
portion.
The impact of antibody subclass
There are 4 subclasses of IgG (IgG1, IgG2, IgG3 and IgG4), and
so far all the sub-classes apart from IgG3 have been used to
develop ADCs that are currently in clinical trials.60
IgG1 is the most commonly used subclass for ADC design. It
has comparable serum stability (21 days) to IgG2 and IgG4 but
has a greater ability to ﬁx complement and a higher afﬁnity for
activating FcgRs expressed on effector cells such as monocytes
and macrophages (FcgRI, FcgRIIa, FcgRIIIa) and natural killer
(NK) cells (FcgRIIIa).61 Therefore, this sub-class has a superior
ability to engage the immune system and trigger CDC, ADCC
and ADCP.
IgG3 has a superior ability to ﬁx complement and to bind
activating FcgRs61 but it has so far been avoided for the devel-
opment of ADCs because of its low half-life in serum compared
to the other classes (e.g., 7 days instead of 21 days for IgG1, 2
and 4), its long hinge region that is subject to proteolysis and
also evidence of potential immunogenicity.62
IgG2 and IgG4 have low or no capacity to ﬁx complement
and have lower afﬁnity for the activating FcgRs compared with
IgG1. IgG2 and IgG4 are used in the design of therapeutic anti-
bodies when the recruitment of the immune system is not
desired. IgG2 has four disulﬁde bridges, while IgG1 and IgG4
have only two, so it seems more suitable for the use of mal-
emide-linkers allowing a higher DAR.63 IgG2 is also able to
form dimers, but the impact of dimerization on its therapeutic
effects would require more in-depth study. IgG2 ADCs, such as
AGS-16M8F (anti-ENPP3 IgG2-MMAF),64 are currently under
evaluation in clinical trials.60,65 IgG4 is a sub-class with very
unusual characteristics, such as the ability to undergo Fab arm
exchange (FAE) with other IgG4 antibodies, and can thus result
in bispeciﬁc and functionally monovalent forms with reduced
anti-target functions.66 Therefore, speciﬁc single point muta-
tions (S228P or S228P/R209K)67,68 are usually introduced to
stabilize the antibody and prevent FAE. Despite lower afﬁnity
for the activating FcgRs compared with IgG1, the afﬁnity of
IgG4 for FcgRI form is sufﬁcient for functional activation66
and in its non-fucosylated form IgG4 is able to bind FcgRIIIa.69
Therefore, immune cell activation needs to be considered, when
designing ADCs with IgG4 antibodies. The ﬁrst ADC approved
by the FDA in 2000 was an IgG4 antibody (Gemtuzumab ozo-
gamicin, anti-CD33 IgG4-Calicheamicin), withdrawn from the
market voluntarily in 2010, since a post approval study showed
no improvements in survival and fatal toxicities. However the
ADC has been re-approved this year for the treatment of acute
myeloid leukemia.12 More IgG4 ADCs are currently being eval-
uated in clinical trials.60,65
Fc domain engineering strategies
Another method to modulate the ability of ADCs to engage the
immune system is to engineer their Fc domains. A widely used
method to enhance their ability to recruit the immune system
and to trigger effector functions is antibody glycoengineering,
such as the production of afucosylated IgGs. J6M0-mcMMAF
(anti-BCMA IgG1-MMAF) is the ﬁrst afucosylated-ADC that
entered a clinical trial for the treatment of multiple myeloma.70
If the sub-class of choice is IgG1, the Fc portion can be engi-
neered to introduce a single point mutation, or a combination
of mutations, to enhance or impair IgG1 binding to FcgRs or
complement (C1q), and consequently to enhance or impair
ADCC, ADCP or CDC.71–73 An example is the Phase I clinical
trial of MEDI4276 (anti-HER2 IgG1-tubulysin analogue) which
has been engineered with three single point mutations (E234F,
S239C and S442C) to reduce FcgR binding with the aim to
minimize thrombocytopenia seen with T-DM1.23
Fc engineering could also be used to improve the pharmaco-
kinetics of ADCs. An example is the humanized IgG1 MEDI-
524-YTE engineered with three single point mutations
(M252Y, S254T and T256E) to enhance IgG1 binding to the
neonatal Fc receptor (FcRn). MEDI-524-YTE has been shown
to have a four-fold increase in serum half-life in cynomolgus
monkeys compared with the wild type antibody.74 It is worth
investigating if increased FcRn binding and longer half-life
might result in increased activity and decreased toxicity for an
ADC.75
ADC design based on biodistribution considerations
Stand-alone small molecule therapeutic agents such as those
conjugated to ADCs can be widely distributed in the body. In
contrast, antibodies are restricted primarily to plasma and
extracellular ﬂuids, and have been shown to target tissues that
express the relevant antigen(s). ADCs typically retain the phar-
macokinetic properties of their antibody component3,76 as
opposed to the attached drug, and thus exhibit relatively low
clearance and longer half-lives.77
Despite the optimization of therapeutic antibodies and
the availability of antibodies with higher afﬁnity for the
tumor than for normal tissues, the amount of antibody that
reaches a tumor is only a small percentage of that adminis-
tered (e.g., approximately 1–2%).1,78,79 For this reason the
use of recombinant antibody fragments for ADC production
has been evaluated. Antibody fragments such as diabodies
are much smaller then IgGs (around 50 kDa versus
150 kDa) and thus have superior tissue penetration abilities.
However, due to their smaller size and the lack of the Fc
portion that usually binds to FcRn, diabodies are cleared
much faster than whole IgG isotypes.80 A promising anti-
CD30 diabody-drug conjugate has already demonstrated
high anti-tumor activity,81 but the use of diabodies for
ADC design needs further study and optimization with a
view to striking a balance between optimum tissue penetra-
tion and low clearance rates.
The Fc portion of an ADC is responsible for ADC-mediated
effector functions and pharmacokinetics. Therefore, these bio-
logical properties can be optimized according to therapeutic
requirements via engineering and glycoengineering.
Conclusion
Over the past decade, research efforts have focused on linker
chemistry and optimizing cytotoxic payloads for ADCs. The
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antibody scaffolds of ADCs provide the required speciﬁcity for
tumor-associated antigens and can be used to transport prohib-
itively-cytotoxic agents to cancer tissues. However, the poten-
tial clinical effects of the choice of antibody and its structural
characteristics remain less-well explored, and perhaps under-
exploited. Emerging evidence and novel technologies now pro-
vide good reason for a closer consideration of antibody struc-
ture, how this is inﬂuenced by linking to toxic payloads, and
how both the antigen-recognizing Fab regions, as well as the
immune-engaging Fc domains, can affect the functions and
potency of ADCs (Fig. 1).
In designing the next generation of more effective, speciﬁc
and efﬁcacious ADCs, we postulate that translational opportu-
nities that can be harnessed by considering the attributes of the
antibody component. Careful selection of linking approaches
could preserve antibody stability and high target afﬁnities may
deﬁne and optimize immune cell engagement functions when
desired. In the future, ADCs with Fc regions of speciﬁc anti-
body isotypes, and with engineered Fc structure scaffolds may
offer better control of biodistribution, and improved immune
cell engagement and activation.
Each component of the tripartite complex can be evaluated
and optimized to deliver pharmacokinetic and oncolytic prop-
erties whilst minimizing off-target toxicities. Novel design
approaches informed by antibody structural attributes may
thus present opportunities to contribute to the success of the
next generation of optimized ADCs.
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